is allulose a glp-1 agonist GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous production and L-cell differentiation | Diabetology & Metabolic Syndrome Secretion of GLP-1 but not
Description
extensive post-market safety data
Treating the chronic disease of obesity
The 12 mg dose produced the most dramatic weight loss results but also the highest incidence of adverse events
Behavioral and Neural Biology
The baseline characteristics of the study populations, study drugs and study designs may be considered as possible reasons for the variability [170]
Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association
